



Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences

May 2, 2022

PASADENA, Calif.--(BUSINESS WIRE)--May 2, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

TIDES USA 2022: Oligonucleotide and Peptide Therapeutics – May 9-12, 2022

Title: **Arrowhead's Approach to Oligonucleotide Scale-Up Manufacturing**
Presenter: Michael Lawler, Director, Chemistry, Arrowhead Pharmaceuticals

2022 American Thoracic Society (ATS) International Conference – May 13-18, 2022

Title: **Silencing RAGE Expression with a Lung-Targeted RNAi Trigger Delivery Platform Suppresses Pulmonary Allergic Inflammation**
Presenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals

Title: **Silencing Muc5ac Expression with a Lung-Targeted RNAi Trigger Prevents Allergen-Induced Mucoobstruction and Airway Hyperresponsiveness**
Presenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals

BofA Securities 2022 Healthcare Conference – May 12, 2022, 1:40 p.m. ET

Type: Fireside chat presentation
Presenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals

2022 RBC Capital Markets Global Healthcare Conference – May 17, 2022, 4:35 p.m. ET

Type: Fireside chat presentation
Presenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals

UBS Global Healthcare Conference 2022 – May 25, 2022, 12:15 p.m. ET

Type: Fireside chat presentation
Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals

A copy of the presentation materials and webcast links may be accessed on the [Events and Presentations](#) page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter [@ArrowheadPharma](https://twitter.com/ArrowheadPharma). To be added to the Company's email list and receive news directly, please visit <http://ir.arrowheadpharma.com/email-alerts>.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," or "continue" are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220502005289/en/): <https://www.businesswire.com/news/home/20220502005289/en/>

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com

Investors:

LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com

Media:

LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361
jo@lifescicomms.com
www.lifescicomms.com

Source: Arrowhead Pharmaceuticals, Inc.